Oslo, 23 January 2024. Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo:
LYTIX), a clinical stage immuno-oncology company, announces that Dr Øystein
Rekdal, CEO, presents the latest developments in the company at Redeye's Fight
Cancer Event 2024. 

The presentation is a live broadcast and can be followed at
https://www.redeye.se/events/966280/redeye-theme-fight-cancer-2 where the replay
and the presentations will be available afterward.

For more information, please contact: 
Gjest Breistein, CFO
E-Mail: gjest.breistein@lytixbiopharma.com

Optimum Strategic Communications
Nick Bastin, Jonathan Edwards
E-mail: lytix@optimumcomms.com

Lytix in brief: 
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
Company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class molecule representing a new and
superior therapeutic principle to kill cancer cells and boost anti-cancer
immunity, with the potential to be the ideal combination partner with other
types of immunotherapies. LTX-315 targets cancer cells and disintegrates their
cell membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens. This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors such as
PBM Capital, a US based, healthcare-focused investment firm.